Fulminant diabetes induced by PD-1 and PD-L1 inhibitors: what about glucose variability?

L. Marchand , S. Reffet , S. Dalle (1, 2, 3) , E. Disse (4) , J. Vouillarmet , C. Cugnet-Anceau , C. Thivolet (4)

1 CHLS - Centre Hospitalier Lyon Sud [CHU - HCL]
2 UCBL - Université Claude Bernard Lyon 1
3 UNICANCER/CRCL - Centre de Recherche en Cancérologie de Lyon
4 CarMeN - Cardiovasculaire, métabolisme, diabétologie et nutrition

Mots clés: Alpha-cell pancreatic function; Anti-PD-1; Anti-PD-L1; Autoimmune diabetes; Beta-cell pancreatic function; Coefficient of variation for glucose; Diabetes mellitus; Exocrine pancreatic function; Flash glucose monitoring; FreeStyle Libre; Fulminant diabetes; Glucose variability; Immune checkpoint inhibitors side effects; Immunotherapy; Labile diabetes; Programmed cell death-1; Programmed death ligand 1

Domaines: Sciences du Vivant [q-bio]

L. Marchand, S. Reffet, S. Dalle, E. Disse, J. Vouillarmet, et al.. Fulminant diabetes induced by PD-1 and PD-L1 inhibitors: what about glucose variability?. Acta Diabetol, 2019, 56 (3), pp.377--378. ⟨10.1007/s00592-018-1262-4⟩. ⟨hal-02195224⟩